BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that the company has appointed Pradeep Bhadauria as Chief Scientific Officer (CSO), effective immediately. He will succeed current CSO Dr. Shankar Hariharan, who is leaving Amneal on May 24, 2019.
Pradeep brings significant R&D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies. Throughout his career, his leadership has resulted in the development and filing of more than 200 products, including numerous first-to-file and first-to-market opportunities.
“We are excited to have Pradeep join our leadership team at this important moment for Amneal,” said Rob Stewart, President and CEO of Amneal. “His deep R&D expertise across nearly all dosage forms and demonstrated strength in developing complex generics and other difficult-to-formulate products will be a strong asset to our company as we continue to diversify our pipeline and portfolio.”
“I would like to thank Shankar for his exceptional contributions during the last nine years with Amneal,” added Stewart. “His leadership and vision have helped deliver the company to the strong position it stands in today, with robust capability and one of the industry’s largest pipelines. Thanks to his efforts, we are well positioned to continue evolving Amneal to support further pipeline and portfolio growth.”
“I am thrilled to be joining Amneal at this exciting time for the company,” said Bhadauria. “I look forward to working closely with Amneal’s excellent Scientific Affairs team to help advance and expand the company’s compelling pipeline and continue bringing important treatment options to patients.”
Pradeep joins Amneal from Apotex, Inc., where he most recently served as Executive Vice President, Global R&D, responsible for leading the company’s entire global R&D activities. He also managed a large generic R&D portfolio across many dosage forms for various global markets. Prior to joining Apotex, he served as Vice President - Generic R&D for Allergan/Actavis.
Pradeep holds a Master of Pharmacy (M.Pharm) from the Birla Institute of Technology in India and a Bachelor of Pharmacy from SGSITS, Devi Ahilya University in India. He also holds several patents and has published research in various publications.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty Pharma division focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.
